重组人白介素11治疗急性白血病化疗后血小板减少的临床疗效

目的 探讨重组人白介素11治疗急性白血病化疗后血小板减少的临床疗效.方法 选取2014年1月至2016年1月于枣阳市第一人民医院收治的急性白血病患者60例作为研究对象.根据随机数表法分为对照组和观察组,各30例,对照组实施常规化疗,观察组实施常规化疗联合重组白细胞介素-11,比较两组患者血小板计数变化.结果 观察组血小板最低值(8.7±2.0)×109/L]与对照组(8.8±1.9)×109/L]比较差异无统计学意义(P>0.05);血小板最高值(162.3±30.2)×109/L]明显高于对照组(90.6±21.7)×109/L,P<0.05]:观察组和对照组患者的血小板恢复时间(11.9±5.2)d vs(15.6±6.0)d]、血小板输入量(7.1±3.1)U vs(10.7±4.2)U]、出血率23.3%vs 63.3%]、不良反应率13.3%vs 66.7%]比较,观察组均明显低于或少于对照组,差异均有统计学意义(P<0.05).结论 重组人白介素11治疗急性白血病化疗后血小板减少的临床疗效较佳,且不良反应发生率低,临床应用安全.

Clinical effect of recombinant human interleukin 11 in treating thrombocytopenia induced by chemotherapy in patients with acute leukemia

Objective To investigate the clinical efficacy of recombinant human interleukin 11 in treating thrombocytopenia induced by chemotherapy in patients with acute leukemia (AL). Methods A total of 60 patients with AL in our hospital from January 2014 to January 2016 were selected as the research objects. According to the random number table, they were divided into control group and observation group, with 30 patients in each group. The control group received routine chemotherapy, while observation group received routine chemotherapy combined with recombi-nant interleukin-11. The changes of platelet count between the two groups were compared. Results The lowest platelet count in observation group and control group were respectively (8.7±2.0)×109/L, and (8.8±1.9)×109/L, with no statistical-ly significant difference between the two groups (P>0.05). The highest platelet count in observation group was (162.3 ± 30.2)×109/L, which was significantly higher than (90.6±21.7)×109/L in control group, P<0.05. The platelet recovery time in observation group was (11.9 ± 5.2) d, which was significantly lower than (15.6 ± 6.0) d in control group, P<0.05. The platelet transfusion was (71±3.1) U in the observation group, which was significantly lower than (10.7±4.2) U in the con-trol group (P<0.05). The blood loss rate of the observation group (23.3%) was significantly lower than that of the control group (63.3%), P<0.05. The adverse reactions of the observation group (13.3%) was significantly lower than that in the control group (66.7%), P<0.05. Conclusion Recombinant human interleukin-11 has better clinical efficacy in treating thrombocytopenia induced by chemotherapy in patients with acute leukemia, which show low incidence of adverse reac-tions and good safety in clinical application.